Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Cochrane Infectious Diseases group, Liverpool School of Tropical Medicine, Liverpool, UK.
Cochrane Database Syst Rev. 2023 Aug 18;8(8):CD011534. doi: 10.1002/14651858.CD011534.pub3.
Acute otitis media (AOM) is one of the most common childhood infectious diseases. Pain is the key symptom of AOM and central to children's and parents' experience of the illness. Because antibiotics provide only marginal benefits, analgesic treatment including paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) is regarded as the cornerstone of AOM management. This is an update of a review first published in 2016.
Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with placebo or no treatment in relieving pain in children with AOM. Our secondary objective was to assess the effectiveness of NSAIDs as compared with paracetamol in children with AOM.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 5, April 2023; MEDLINE (Ovid, from 1946 to May 2023), Embase (from 1947 to May 2023), CINAHL (from 1981 to May 2023), LILACS (from 1982 to May 2023), and Web of Science Core Collection (from 1955 to May 2023). We searched the WHO ICTRP and ClinicalTrials.gov for completed and ongoing trials (23 May 2023).
We included randomised controlled trials comparing the effectiveness of paracetamol or NSAIDs, alone or combined, for pain relief in non-hospitalised children aged six months to 16 years with AOM. We also included trials of paracetamol or NSAIDs, alone or combined, for children with fever or upper respiratory tract infections if we were able to extract subgroup data on pain relief in children with AOM either directly or after obtaining additional data from study authors. We extracted and summarised data for the following comparisons: paracetamol versus placebo, NSAIDs versus placebo, NSAIDs versus paracetamol, and NSAIDs plus paracetamol versus paracetamol alone.
We used standard methodological procedures expected by Cochrane. We rated the overall certainty of evidence for each outcome of interest using the GRADE approach.
We included four trials (411 children) which were assessed at low to high risk of bias. Paracetamol versus placebo Data from one trial (148 children) informed this comparison. Paracetamol may be more effective than placebo in relieving pain at 48 hours (proportion of children with pain 10% versus 25%, risk ratio (RR) 0.38, 95% confidence interval (CI) 0.17 to 0.85; number needed to treat for an additional beneficial outcome (NNTB) 7; low-certainty evidence). The evidence is very uncertain about the effects of paracetamol on fever at 48 hours (RR 1.03, 95% CI 0.07 to 16.12; very low-certainty evidence) and adverse events (RR 1.03, 95% CI 0.21 to 4.93; very low-certainty evidence). No data were available for our other outcomes of interest. NSAIDs versus placebo Data from one trial (146 children) informed this comparison. Ibuprofen may be more effective than placebo in relieving pain at 48 hours (proportion of children with pain 7% versus 25%, RR 0.28, 95% CI 0.11 to 0.70; NNTB 6; low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen on fever at 48 hours (RR 1.06, 95% CI 0.07 to 16.57; very low-certainty evidence) and adverse events (RR 1.76, 95% CI 0.44 to 7.10; very low-certainty evidence). No data were available for our other outcomes of interest. NSAIDs versus paracetamol Data from four trials (411 children) informed this comparison. The evidence is very uncertain about the effect of ibuprofen versus paracetamol in relieving ear pain at 24 hours (RR 0.83, 95% CI 0.59 to 1.18; 2 RCTs, 39 children; very low-certainty evidence); 48 to 72 hours (RR 0.91, 95% CI 0.54 to 1.54; 3 RCTs, 183 children; low-certainty evidence); and four to seven days (RR 0.74, 95% CI 0.17 to 3.23; 2 RCTs, 38 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol on mean pain score at 24 hours (0.29 lower, 95% CI 0.79 lower to 0.20 higher; 3 RCTs, 111 children; very low-certainty evidence); 48 to 72 hours (0.25 lower, 95% CI 0.66 lower to 0.16 higher; 3 RCTs, 108 children; very low-certainty evidence); and four to seven days (0.30 higher, 95% CI 1.78 lower to 2.38 higher; 2 RCTs, 31 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol in resolving fever at 24 hours (RR 0.69, 95% CI 0.24 to 2.00; 2 RCTs, 39 children; very low-certainty evidence); 48 to 72 hours (RR 1.18, 95% CI 0.31 to 4.44; 3 RCTs, 182 children; low-certainty evidence); and four to seven days (RR 2.75, 95% CI 0.12 to 60.70; 2 RCTs, 39 children; very low-certainty evidence). The evidence is very uncertain about the effect of ibuprofen versus paracetamol on adverse events (RR 1.71, 95% CI 0.43 to 6.90; 3 RCTs, 281 children; very low-certainty evidence); reconsultations (RR 1.13, 95% CI 0.92 to 1.40; 1 RCT, 53 children; very low-certainty evidence); and delayed antibiotic prescriptions (RR 1.32, 95% CI 0.74 to 2.35; 1 RCT, 53 children; very low-certainty evidence). No data were available on time to resolution of pain. NSAIDs plus paracetamol versus paracetamol alone Data on the effectiveness of ibuprofen plus paracetamol versus paracetamol alone came from two trials that provided crude subgroup data for 71 children with AOM. The small sample provided imprecise effect estimates, therefore we were unable to draw any firm conclusions (very low-certainty evidence).
AUTHORS' CONCLUSIONS: Despite explicit guideline recommendations on the use of analgesics in children with AOM, the current evidence on the effectiveness of paracetamol or NSAIDs, alone or combined, in children with AOM is limited. Paracetamol and ibuprofen as monotherapies may be more effective than placebo in relieving short-term ear pain in children with AOM. The evidence is very uncertain for the effect of ibuprofen versus paracetamol on relieving short-term ear pain in children with AOM, as well as for the effectiveness of ibuprofen plus paracetamol versus paracetamol alone, thereby preventing any firm conclusions. Further research is needed to provide insights into the role of ibuprofen as adjunct to paracetamol, and other analgesics such as anaesthetic eardrops, for children with AOM.
急性中耳炎 (AOM) 是最常见的儿童传染性疾病之一。疼痛是 AOM 的关键症状,也是儿童及其父母患病体验的核心。由于抗生素的疗效有限,因此包括扑热息痛(对乙酰氨基酚)和非甾体抗炎药(NSAIDs)在内的镇痛治疗被视为 AOM 管理的基石。这是一篇 2016 年首次发表的综述的更新。
我们的主要目的是评估在 AOM 儿童中,与安慰剂或不治疗相比,扑热息痛(对乙酰氨基酚)或 NSAIDs 单独或联合使用在缓解疼痛方面的有效性。我们的次要目的是评估 NSAIDs 与扑热息痛(对乙酰氨基酚)相比在 AOM 儿童中的有效性。
我们检索了 Cochrane 对照试验中心注册库(CENTRAL),2023 年第 5 期;MEDLINE(Ovid,从 1946 年至 2023 年 5 月)、Embase(从 1947 年至 2023 年 5 月)、CINAHL(从 1981 年至 2023 年 5 月)、LILACS(从 1982 年至 2023 年 5 月)和 Web of Science 核心合集(从 1955 年至 2023 年 5 月)。我们还在世界卫生组织国际临床试验注册平台(ICTRP)和 ClinicalTrials.gov 上搜索了已完成和正在进行的试验(2023 年 5 月 23 日)。
我们纳入了比较非住院儿童(6 个月至 16 岁)在 AOM 中使用扑热息痛或 NSAIDs 单独或联合治疗以缓解疼痛的有效性的随机对照试验。如果我们能够直接从试验中提取 AOM 儿童疼痛缓解的亚组数据,或者从研究作者那里获得额外的数据,我们还纳入了扑热息痛或 NSAIDs 用于治疗发热或上呼吸道感染的儿童的试验,但我们仅纳入了有关 AOM 儿童疼痛缓解的数据。我们提取并总结了以下比较的结果:扑热息痛与安慰剂、NSAIDs 与安慰剂、NSAIDs 与扑热息痛以及 NSAIDs 加扑热息痛与扑热息痛单独使用的比较。
我们使用了 Cochrane 预期的标准方法学程序。我们使用 GRADE 方法评估了每个感兴趣结局的证据总体确定性。
我们纳入了四项试验(411 名儿童),这些试验的偏倚风险评估为低至高。扑热息痛与安慰剂:一项试验(148 名儿童)提供了这一比较的数据。与安慰剂相比,扑热息痛可能更有效地缓解 48 小时的疼痛(疼痛比例为 10%对 25%,RR 0.38,95% CI 0.17 至 0.85;NNTB 为 7;低确定性证据)。扑热息痛对 48 小时的发热(RR 1.03,95% CI 0.07 至 16.12;非常低确定性证据)和不良事件(RR 1.03,95% CI 0.21 至 4.93;非常低确定性证据)的影响的证据非常不确定。我们的其他结局的证据也非常有限。NSAIDs 与安慰剂:一项试验(146 名儿童)提供了这一比较的数据。与安慰剂相比,布洛芬可能更有效地缓解 48 小时的疼痛(疼痛比例为 7%对 25%,RR 0.28,95% CI 0.11 至 0.70;NNTB 为 6;低确定性证据)。布洛芬对 48 小时发热(RR 1.06,95% CI 0.07 至 16.57;非常低确定性证据)和不良事件(RR 1.76,95% CI 0.44 至 7.10;非常低确定性证据)的影响的证据非常不确定。我们的其他结局的证据也非常有限。NSAIDs 与扑热息痛:四项试验(411 名儿童)的数据提供了这一比较的数据。布洛芬与扑热息痛相比在缓解 24 小时内耳部疼痛的效果的证据非常不确定(RR 0.83,95% CI 0.59 至 1.18;2 项 RCT,39 名儿童;非常低确定性证据);48 至 72 小时(RR 0.91,95% CI 0.54 至 1.54;3 项 RCT,183 名儿童;低确定性证据);以及 4 至 7 天(RR 0.74,95% CI 0.17 至 3.23;2 项 RCT,38 名儿童;非常低确定性证据)。布洛芬与扑热息痛相比在 24 小时内平均疼痛评分的影响的证据非常不确定(疼痛评分低 0.29,95% CI 疼痛评分低 0.79 至高 0.20;3 项 RCT,111 名儿童;非常低确定性证据);48 至 72 小时(疼痛评分低 0.25,95% CI 疼痛评分低 0.66 至高 0.16;3 项 RCT,108 名儿童;非常低确定性证据);以及 4 至 7 天(疼痛评分高 0.30,95% CI 疼痛评分高 1.78 至高 2.38;2 项 RCT,31 名儿童;非常低确定性证据)。布洛芬与扑热息痛相比在缓解发热的效果的证据非常不确定(RR 0.69,95% CI 0.24 至 2.00;2 项 RCT,39 名儿童;非常低确定性证据);48 至 72 小时(RR 1.18,95% CI 0.31 至 4.44;3 项 RCT,182 名儿童;低确定性证据);以及 4 至 7 天(RR 2.75,95% CI 0.12 至 60.70;2 项 RCT,39 名儿童;非常低确定性证据)。布洛芬与扑热息痛相比在不良事件(RR 1.71,95% CI 0.43 至 6.90;3 项 RCT,281 名儿童;非常低确定性证据);再就诊(RR 1.13,95% CI 0.92 至 1.40;1 项 RCT,53 名儿童;非常低确定性证据);以及延迟开抗生素处方(RR 1.32,95% CI 0.74 至 2.35;1 项 RCT,53 名儿童;非常低确定性证据)的影响的证据非常不确定。我们没有关于疼痛缓解时间的数据。NSAIDs 加扑热息痛与扑热息痛单独使用:来自两项试验的关于布洛芬加扑热息痛与扑热息痛单独使用的有效性的数据提供了亚组数据,这两项试验的亚组数据涉及 71 名患有 AOM 的儿童。小样本提供了不精确的效应估计,因此我们无法得出任何明确的结论(非常低确定性证据)。
尽管有明确的指南建议使用镇痛药治疗 AOM 儿童,但目前关于 AOM 儿童使用扑热息痛或 NSAIDs 单独或联合使用的有效性的证据有限。扑热息痛和布洛芬作为单药治疗可能比安慰剂更有效地缓解 AOM 儿童的短期耳部疼痛。布洛芬与扑热息痛相比在缓解 AOM 儿童短期耳部疼痛的效果方面的证据非常不确定,以及布洛芬加扑热息痛与扑热息痛单独使用的效果也不确定,因此无法得出任何明确的结论。需要进一步的研究来提供关于布洛芬作为扑热息痛的辅助治疗以及其他镇痛药(如麻醉性滴耳液)在 AOM 儿童中的作用的见解。